INCY
Incyte Corporation NASDAQ Listed Nov 4, 1993$97.75
Mkt Cap $19.5B
52w Low $57.77
73.3% of range
52w High $112.29
50d MA $95.56
200d MA $93.94
P/E (TTM)
14.7x
EV/EBITDA
9.2x
P/B
3.7x
Debt/Equity
0.0x
ROE
25.5%
P/FCF
14.2x
RSI (14)
—
ATR (14)
—
Beta
0.86
50d MA
$95.56
200d MA
$93.94
Avg Volume
1.7M
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
1801 Augustine Cut-Off · Wilmington, DE 19803 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28, 2026 | TNS | 1.38 | 1.81 | +31.2% | 97.74 | +1.5% | +1.4% | -2.5% | -0.8% | -0.6% | -0.5% | — |
| Feb 10, 2026 | TNS | 1.90 | 1.80 | -5.3% | 100.05 | -1.5% | -1.2% | +0.7% | +1.0% | +1.1% | +2.9% | — |
| Oct 28, 2025 | TNS | 1.66 | 2.26 | +36.1% | 91.65 | -0.2% | -1.6% | +1.0% | +2.0% | +10.8% | +12.3% | — |
| Jul 29, 2025 | TNS | 1.39 | 1.57 | +12.9% | 77.38 | +0.6% | +0.2% | -3.2% | -2.3% | +0.9% | +0.4% | — |
| Apr 29, 2025 | TNS | 1.01 | 1.16 | +14.9% | 60.43 | +0.9% | +3.7% | +2.6% | +3.5% | +2.8% | -1.4% | — |
| Feb 10, 2025 | TNS | 1.57 | 1.43 | -8.9% | 68.30 | -1.1% | -2.9% | +1.1% | +2.5% | +3.1% | +4.3% | — |
| Oct 29, 2024 | TNS | 1.12 | 1.07 | -4.5% | 73.60 | +0.0% | +0.4% | +0.7% | +3.4% | +2.9% | +5.0% | — |
| Jul 30, 2024 | TNS | 0.78 | -1.82 | -333.3% | 67.79 | +0.1% | -4.0% | -5.0% | -4.9% | -8.5% | -9.6% | — |
| Apr 30, 2024 | TNS | 0.84 | 0.64 | -23.8% | 52.05 | -0.3% | +1.7% | +2.0% | +3.3% | +3.9% | +4.5% | — |
| Feb 13, 2024 | TNS | 1.16 | 1.06 | -8.6% | 59.34 | -1.3% | -2.4% | -0.6% | -2.3% | -0.9% | +1.7% | — |
| Oct 31, 2023 | TNS | 1.09 | 1.10 | +0.9% | 53.93 | +0.1% | +0.8% | +0.1% | +1.7% | +1.2% | +1.5% | — |
| Aug 1, 2023 | TNS | 0.83 | 0.99 | +19.3% | 63.69 | +0.2% | +3.1% | +2.0% | -0.1% | +1.9% | +1.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29 | Stifel | Maintains | Buy → Buy | — | $97.74 | $99.18 | +1.5% | +1.4% | -2.5% | -0.8% | -0.6% | -0.3% |
| Apr 29 | Oppenheimer | Maintains | Perform → Perform | — | $97.74 | $99.18 | +1.5% | +1.4% | -2.5% | -0.8% | -0.6% | -0.3% |
| Apr 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $97.69 | $98.75 | +1.1% | -0.6% | -2.4% | +0.1% | -0.8% | -1.5% |
| Mar 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $90.30 | $91.13 | +0.9% | +0.0% | +4.2% | +4.4% | +6.2% | +5.0% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $90.62 | $91.00 | +0.4% | +1.8% | +1.8% | -0.4% | -0.3% | +3.9% |
| Mar 25 | UBS | Maintains | Neutral → Neutral | — | $90.62 | $91.00 | +0.4% | +1.8% | +1.8% | -0.4% | -0.3% | +3.9% |
| Mar 16 | Jefferies | Downgrade | Buy → Hold | — | $92.54 | $92.14 | -0.4% | +0.5% | +1.8% | -0.3% | +0.4% | -1.9% |
| Mar 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $95.94 | $95.94 | +0.0% | +1.2% | +0.1% | -1.3% | -4.1% | -3.5% |
| Mar 5 | Evercore ISI | Maintains | In Line → In Line | — | $98.86 | $97.99 | -0.9% | -1.5% | -3.0% | -1.8% | -2.9% | -4.2% |
| Feb 18 | Barclays | Maintains | Overweight → Overweight | — | $101.16 | $100.77 | -0.4% | +1.8% | +0.6% | +0.2% | -0.3% | -0.1% |
| Feb 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $100.05 | $98.52 | -1.5% | -1.2% | +0.7% | +1.0% | +1.1% | +2.9% |
| Feb 11 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $100.05 | $98.52 | -1.5% | -1.2% | +0.7% | +1.0% | +1.1% | +2.9% |
| Feb 11 | Stifel | Maintains | Buy → Buy | — | $100.05 | $98.52 | -1.5% | -1.2% | +0.7% | +1.0% | +1.1% | +2.9% |
| Feb 11 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $100.05 | $98.52 | -1.5% | -1.2% | +0.7% | +1.0% | +1.1% | +2.9% |
| Feb 6 | Piper Sandler | Maintains | Overweight → Overweight | — | $102.76 | $103.75 | +1.0% | +5.5% | +6.1% | -2.6% | -3.8% | -2.0% |
| Feb 4 | Barclays | Maintains | Overweight → Overweight | — | $100.92 | $102.61 | +1.7% | +1.7% | +1.8% | +7.4% | +8.0% | -0.9% |
| Jan 20 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $106.21 | $103.26 | -2.8% | -3.4% | -1.4% | -1.1% | -4.0% | -3.4% |
| Jan 13 | TD Cowen | Maintains | Buy → Buy | — | $106.33 | $106.56 | +0.2% | -2.7% | -0.4% | -1.0% | -0.1% | -3.5% |
| Jan 6 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $101.79 | $101.73 | -0.1% | +4.8% | +8.6% | +4.1% | +5.0% | +4.5% |
| Dec 8 | Mizuho | Upgrade | Neutral → Outperform | — | $102.52 | $100.13 | -2.3% | -5.7% | -7.2% | -7.2% | -6.3% | -6.9% |
| Dec 8 | Wells Fargo | Maintains | Overweight → Overweight | — | $102.52 | $100.13 | -2.3% | -5.7% | -7.2% | -7.2% | -6.3% | -6.9% |
| Dec 8 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $102.52 | $100.13 | -2.3% | -5.7% | -7.2% | -7.2% | -6.3% | -6.9% |
| Nov 24 | Barclays | Maintains | Overweight → Overweight | — | $102.06 | $103.00 | +0.9% | +4.1% | +3.4% | +3.5% | +2.4% | -0.0% |
| Nov 4 | Piper Sandler | Maintains | Overweight → Overweight | — | $101.57 | $101.85 | +0.3% | +1.3% | +4.1% | +3.6% | +4.3% | +4.3% |
| Nov 3 | Guggenheim | Upgrade | Neutral → Buy | — | $93.48 | $93.95 | +0.5% | +8.7% | +10.1% | +13.1% | +12.5% | +13.4% |
| Oct 29 | Wells Fargo | Maintains | Overweight → Overweight | — | $91.65 | $91.49 | -0.2% | -1.6% | +1.0% | +2.0% | +10.8% | +12.3% |
| Oct 29 | Truist | Maintains | Hold → Hold | — | $91.65 | $91.49 | -0.2% | -1.6% | +1.0% | +2.0% | +10.8% | +12.3% |
| Oct 29 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $91.65 | $91.49 | -0.2% | -1.6% | +1.0% | +2.0% | +10.8% | +12.3% |
| Oct 29 | Barclays | Maintains | Overweight → Overweight | — | $91.65 | $91.49 | -0.2% | -1.6% | +1.0% | +2.0% | +10.8% | +12.3% |
| Oct 9 | JP Morgan | Maintains | Neutral → Neutral | — | $85.38 | $85.55 | +0.2% | -0.7% | -1.9% | -0.8% | +0.7% | +3.2% |
| Sep 24 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $84.54 | $84.19 | -0.4% | -0.4% | -3.4% | -2.2% | -0.8% | +0.3% |
| Sep 22 | Stifel | Maintains | Buy → Buy | — | $86.53 | $86.39 | -0.2% | -2.1% | -2.3% | -2.7% | -5.6% | -4.4% |
| Sep 19 | Guggenheim | Maintains | Neutral → Neutral | — | $86.00 | $85.86 | -0.2% | +0.6% | -1.5% | -1.7% | -2.1% | -5.0% |
| Sep 4 | BofA Securities | Maintains | Buy → Buy | — | $86.96 | $87.26 | +0.3% | -1.7% | -0.4% | -0.5% | -1.6% | -0.8% |
| Aug 22 | JP Morgan | Maintains | Neutral → Neutral | — | $86.53 | $87.00 | +0.5% | -1.7% | -2.0% | -2.9% | -2.0% | -3.3% |
| Aug 6 | Wells Fargo | Upgrade | Equal Weight → Overweight | — | $77.72 | $78.62 | +1.2% | -0.1% | +0.6% | +0.9% | +1.9% | +5.0% |
| Jul 30 | UBS | Maintains | Neutral → Neutral | — | $77.38 | $77.84 | +0.6% | +0.2% | -3.2% | -2.3% | +0.9% | +0.4% |
| Jul 30 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $77.38 | $77.84 | +0.6% | +0.2% | -3.2% | -2.3% | +0.9% | +0.4% |
| Jul 30 | Citigroup | Maintains | Buy → Buy | — | $77.38 | $77.84 | +0.6% | +0.2% | -3.2% | -2.3% | +0.9% | +0.4% |
| Jul 30 | BMO Capital | Maintains | Underperform → Underperform | — | $77.38 | $77.84 | +0.6% | +0.2% | -3.2% | -2.3% | +0.9% | +0.4% |
| Jul 30 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $77.38 | $77.84 | +0.6% | +0.2% | -3.2% | -2.3% | +0.9% | +0.4% |
| Jul 30 | Truist | Maintains | Hold → Hold | — | $77.38 | $77.84 | +0.6% | +0.2% | -3.2% | -2.3% | +0.9% | +0.4% |
| Jul 14 | JP Morgan | Maintains | Neutral → Neutral | — | $68.59 | $68.77 | +0.3% | +2.0% | -0.5% | +0.9% | +0.5% | -1.1% |
| Jun 16 | Stifel | Upgrade | Hold → Buy | — | $67.75 | $70.80 | +4.5% | +5.1% | +1.6% | +0.8% | +1.0% | -0.7% |
| Jun 3 | UBS | Maintains | Neutral → Neutral | — | $65.31 | $65.12 | -0.3% | +2.8% | +3.2% | +3.0% | +5.3% | +7.0% |
| May 27 | Truist | Maintains | Hold → Hold | — | $64.25 | $64.95 | +1.1% | +1.7% | +1.1% | +2.8% | +1.3% | +1.6% |
| Apr 30 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $60.43 | $60.95 | +0.9% | +3.7% | +2.6% | +3.5% | +2.8% | -1.4% |
| Apr 30 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $60.43 | $60.95 | +0.9% | +3.7% | +2.6% | +3.5% | +2.8% | -1.4% |
| Apr 21 | JP Morgan | Maintains | Neutral → Neutral | — | $58.21 | $57.48 | -1.3% | -2.4% | -1.4% | -0.4% | +1.3% | +1.6% |
| Apr 9 | UBS | Maintains | Neutral → Neutral | — | $56.97 | $55.81 | -2.0% | +3.3% | -3.2% | -0.2% | +3.9% | +2.6% |
No insider trades available.
8-K · 1.01
!! High
MacroGenics, Inc. -- 8-K 1.01: License Agreement
MacroGenics licensed technology to Sage Therapeutics for $60 million upfront, providing near-term revenue while validating its platform and potentially generating future royalties.
May 4
8-K
Incyte Genomics Inc -- 8-K Filing
Incyte delivered strong Q1 2026 results with 20% year-over-year net sales growth, demonstrating solid commercial execution and providing positive momentum heading into the remainder of the year.
Apr 28
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Incyte's executive departure signals potential strategic uncertainty, which could concern investors if the departing executive held critical operational or R&D responsibilities affecting pipeline progress or earnings guidance.
Mar 30
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Incyte's executive leadership restructuring signals management confidence in executing strategy, though investors should monitor whether these appointments strengthen drug development pipelines or indicate preparation for operational challenges ahead.
Mar 26
8-K · 8.01
!! High
Incyte Genomics Inc -- 8-K 8.01: Material Event / Announcement
Incyte received an FDA Complete Response Letter for Zynyz in lung cancer, delaying the supplemental approval despite positive Phase 3 trial data, requiring additional information before resubmission.
Mar 6
8-K
Incyte Genomics Inc -- 8-K Filing
Incyte reported strong fourth quarter and full-year 2025 results driven by core business growth and pipeline advancement, while providing 2026 financial guidance to investors.
Feb 10
Data updated apr 25, 2026 3:30pm
· Source: massive.com